<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905446</url>
  </required_header>
  <id_info>
    <org_study_id>1581811</org_study_id>
    <nct_id>NCT04905446</nct_id>
  </id_info>
  <brief_title>Measurement of NAD+ Synthesis in Human Skeletal Muscle</brief_title>
  <acronym>NAD-flux</acronym>
  <official_title>Measurement of NAD+ Synthesis in Human Skeletal Muscle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The key objective of this pilot research study is to dose human volunteers with a heavy&#xD;
      (non-radioactive) isotope derivative of nicotinamide to detect NAD synthesis in human&#xD;
      skeletal muscle. The ultimate goal is to examine the impact of lifestyle choices, aging,&#xD;
      nutraceuticals, and drugs on the rate of NAD synthesis in human subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of NAD+ mass isotopomers in extracts from human muscle and skin tissue biopsies as determined by liquid chromatography-mass spectrometry (LC-MS)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Skeletal Muscle</condition>
  <arm_group>
    <arm_group_label>Healthy male subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Deuterated nicotinamide (D4-NAM) IV infusion</intervention_name>
    <description>Nicotinamide adenine dinucleotide (NAD) is a vitally important substance that is found in all cells of the body. D4-NAM (in normal saline) will be infused via an indwelling catheter.The IV infusion will continue for 8 hrs.</description>
    <arm_group_label>Healthy male subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skeletal muscle biopsy</intervention_name>
    <description>Participants will have a muscle biopsy performed on the muscle in the thigh. We will collect a small sample of blood before the biopsy. This procedure is used to sample muscle cells from the right or left leg Vastus Lateralis (thigh) muscle.</description>
    <arm_group_label>Healthy male subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin tissue biopsy</intervention_name>
    <description>This procedure is used to sample skin tissue from the upper thigh via a punch biopsy.</description>
    <arm_group_label>Healthy male subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subjects who, at the time of screening are between the ages of 21 to 40&#xD;
             years of age, inclusive.&#xD;
&#xD;
          2. BMI between 20-30 kg/m2 at the screening visit (SV)&#xD;
&#xD;
          3. Understands the procedures and agrees to participate by giving written informed&#xD;
             consent&#xD;
&#xD;
          4. Willing and able to comply with the scheduled study day and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Acute or chronic medical conditions or medication that would contraindicate the&#xD;
        participation in the research testing or could potentially affect metabolic function&#xD;
        including, but not limited to:&#xD;
&#xD;
          1. History of type 1 or type 2 diabetes mellitus, including pre-diabetes (HbA1c &gt; 5.7)&#xD;
&#xD;
          2. History of any antihyperglycemic agent (e.g., insulin)&#xD;
&#xD;
          3. Currently taking medications that can alter glucose homeostasis (e.g., steroids,&#xD;
             glucocorticoids, nicotinic acid) or skeletal muscle metabolism&#xD;
&#xD;
          4. History of taking Tru Niagen, Basis (or any other NR-containing NAD+ booster) or&#xD;
             niacin supplements.&#xD;
&#xD;
          5. Any bleeding disorders&#xD;
&#xD;
          6. Currently taking any aspirin (ASA) (including baby ASA) or NSAIDs (ibuprofen,&#xD;
             naproxen, etc.) that cannot be safely stopped throughout the study. There is a&#xD;
             recommended hold on NSAIDs and/or ASA for at least 2 days prior to biopsy, although&#xD;
             not exclusionary&#xD;
&#xD;
          7. Presence of bruising in lower extremities&#xD;
&#xD;
          8. Any major surgery within the past 3 months&#xD;
&#xD;
          9. Any acute or chronic infections&#xD;
&#xD;
         10. Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological or&#xD;
             allergic diseases, but excluding untreated, asymptomatic, seasonal allergies at the&#xD;
             time of intervention.&#xD;
&#xD;
         11. Previous difficulty with lidocaine or other local anesthetic agents&#xD;
&#xD;
         12. Thyroid dysfunction (suppressed TSH, elevated TSH &lt;10 µIU/ml if symptomatic or&#xD;
             elevated TSH &gt;10 µIU/ml if asymptomatic)&#xD;
&#xD;
         13. Uncontrolled hypertension (BP &gt;160 mmHg systolic or &gt;100 mmHg diastolic)&#xD;
&#xD;
         14. Use of tobacco or nicotine-containing products within the last 12 months.&#xD;
&#xD;
         15. Chronic kidney disease with GFR of &lt; 60&#xD;
&#xD;
         16. Anemia (hemoglobin &lt;12 g/dl) during screening&#xD;
&#xD;
         17. History of human immunodeficiency virus (HIV), hepatitis B or hepatitis C&#xD;
&#xD;
         18. Liver function testing for ALT or AST greater than or equal to 2 times the upper limit&#xD;
             of normal&#xD;
&#xD;
         19. Participation in studies involving investigational drug(s) within 30 days prior to&#xD;
             Screening visit&#xD;
&#xD;
         20. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more&#xD;
             within 56 days prior to Screening (participants may not donate blood any time during&#xD;
             the study, through the final study day)&#xD;
&#xD;
         21. Presence of any condition that, in the opinion of the Investigator, compromises&#xD;
             participant safety or data integrity or the participant's ability to complete study&#xD;
             days Labs may be repeated at the discretion of the PI, MI or Sub-investigators&#xD;
             (Sub-I).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Gardell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Investigator, Translational Research Institute, AdventHealth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Department</last_name>
    <phone>407-303-7100</phone>
    <email>Fh.tri.recruitment@adventhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AdventHealth Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>407-303-7100</phone>
      <email>Fh.tri.recruitment@adventhealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

